Zobrazeno 1 - 10
of 63
pro vyhledávání: '"John L. Magnani"'
Autor:
Daniel D. Myers, William E. Fogler, John L. Magnani, Thomas W. Wakefield, Suman L. Sood, Angela E. Hawley, Robert E. Sigler, Laura Durham, Michael Holinstat, Veronica Dunivant, Garrett Reynolds, Kiley Crego, Reheman Adili, Patrick A Lester, Junjie Ning
Publikováno v:
Journal of Vascular Surgery: Venous and Lymphatic Disorders. 10:211-220
Background This study evaluated E-selectin inhibition with GMI-1271 (Uproleselan [GMI]) alone and in combination with the standard of care low-molecular-weight heparin (LMWH) to improve vein recanalization, decrease vein wall inflammation and protect
Autor:
Garrett Reynolds, Zoe Zimmerman, Michael Holinstat, Reheman Adili, Patrick A Lester, Suman L. Sood, Daniel D. Myers, Robert E. Sigler, Kiley Crego, Angela E. Hawley, Laura Durham, Veronica Dunivant, William E. Fogler, Thomas W. Wakefield, John L. Magnani
Publikováno v:
Journal of Vascular Surgery: Venous and Lymphatic Disorders. 8:268-278
There is an inter-relationship between thrombosis and inflammation. Previously, we have shown the importance of P-selectin in thrombogenesis and thrombus resolution in many preclinical animal models. The role of E-selectin has been explored in rodent
Autor:
Daniel D. Myers, Martina V Hemmer, Angela E. Hawley, Suman L. Sood, John L. Magnani, Jordan K. Schaefer, Dana E. Angelini, Thomas W. Wakefield, Susan Blackburn, Helen M. Thackray, Sumana Devata
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 2, Pp 193-204 (2020)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis
Background There is an unmet need for antithrombotic treatments for venous thromboembolic disease that do not increase bleeding risk. Selectins are cell adhesion molecules that augment thrombosis by activating immune cells to initiate the coagulation
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Neutrophils are essential to protect the host against invading pathogens but can promote disease progression in sickle cell disease (SCD) by becoming adherent to inflamed microvascular networks in peripheral tissue throughout the body. During the inf
Autor:
Helen M. Thackray, Eric J. Feldman, Brian A. Jonas, Daniel J. DeAngelo, Dale L. Bixby, Jane L. Liesveld, Paula Marlton, John L. Magnani, Anjali S. Advani, Michael O'Dwyer, Pamela S. Becker
Publikováno v:
Blood. 139(8)
Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A phase 1/2 study ev
Autor:
Trevor T. Price, Andrew S. Murray, William E. Fogler, John L. Magnani, P. Kelly Marcom, Eric J. Feldman, Dorothy A. Sipkins, Helen M. Thackray
Publikováno v:
Cancer Research. 81:CT144-CT144
Pre-clinical and clinical data suggest that the bone marrow (BM) environment provides breast cancer (BC) cells a protective haven against chemotherapeutic insult, endocrine therapies, and immune recognition. Novel agents that intercept cross-talk bet
Autor:
Jay N. Lozier, James G. Taylor, Yves D. Pastore, Beng Fuh, David Robert John Readett, R. Clark Brown, Jennifer A. Rothman, Carlton Dampier, Fuad El Rassi, Kathryn L. Hassell, Helen M. Thackray, Theodore Wun, John L. Magnani, Marilyn J. Telen, Wally R. Smith, Julie Kanter, Payal Desai
Publikováno v:
Blood. 136:18-19
Vaso-Occlusive Crises (VOCs) in patients with SCD cause acute and chronic morbidity including disabling pain, hospitalizations, missed school and work, end-organ damage, and early mortality. VOC prophylaxis, while beneficial, does not address the dis
Autor:
Ralph Weissleder, Benoit Tricot, Matthias Nahrendorf, Yoshiko Iwamoto, Friedrich Felix Hoyer, Filip K. Swirski, John L. Magnani, Yuan Sun, Partha Dutta
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 36:1802-1808
Objective— Atherosclerosis is a chronic disease characterized by lipid accumulation in the arterial wall. After myocardial infarction (MI), atherosclerotic plaques are infiltrated by inflammatory myeloid cells that aggravate the disease and increas
Autor:
Feda Azab, Justin King, Abdel Kareem Azab, Daniel Kohnen, Ravi Vij, Barbara Muz, William E. Fogler, John L. Magnani, Mark A. Fiala, Theodore A.G. Smith
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-6 (2019)
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-6 (2019)
Autor:
Kyung Hee Chang, Weiguo Zhang, William E. Fogler, John L. Magnani, Mahesh Basyal, Michael Andreeff, Lauren B Ostermann
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Acute myeloid leukemia (AML) is an aggressive heterogeneous hematologic disease with high mortality in patients older than 60 years. Clinical studies have proven that combinations of FDA-approved Bcl-2 inhibitor, venetoclax and hypomethylating agents